Treatment patterns, healthcare resource utilization, and costs in Medicare patients with diffuse large B-cell lymphoma: a retrospective claims analysis (2015–2020)
No clear standard of care exists in 3 L therapy for older adults with relapsed/refractory DLBCL. The economic burden of DLBCL intensifies with each progressing line of therapy, thus underscoring the need for additional therapeutic options.
Authors
- Alex Mutebi
- Anthony Wang (ORCID: https://orcid.org/0000-0002-9509-6257)
- Fernando Rivas Navarro
- Anupama Kalsekar
- Anindit Chhibber
- Monika Jun
- Tongsheng Wang (ORCID: https://orcid.org/0000-0003-0840-407X)
- Allison Keshishian (ORCID: https://orcid.org/0000-0002-9986-1227)
- Jing He (ORCID: https://orcid.org/0009-0000-4769-0473)
- Chenxue Liang
Institutions
- Genmab (United States) (US)
- AbbVie (United States) (US)
- Genesis Medical Center (US)
- Genesis Research Institute (JP)
- Genmab (Denmark) (DK)
- AbbVie (Japan)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1080/13696998.2024.2399435
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- AbbVie